ous.eversensediabetes.comSenseonics | Eversense Diabetes Monitoring System

Payers Senseonics Accessibility Region: GlobalUSA Global Search × Long Term CGM New to CGM Upgrading to Long-Term CGM Products Eversense CGM System Eversense Sensor Eversense Smart Transmitter Eversense CGM Mobile App Eversense Data Management System Eversense NOW Remote Monitoring Healthcare Providers Patient Case Studies CGM Comparison Why Eversense? Benefits of Long-Term CGM Clinical Evidence Clinic Resources Patient Education Asset Library Compatibility Eversense Distribution Partners Frequently Asked Questions User Guides Eversense Community Join Today Volunteer Ambassadors Eversense Ambassador Profiles Contact Us Sign InEversense XL - up to 180 days of Freedom Say hello to the Eversense XL Continuous Glucose Monitoring (CGM) System, A new alternative to traditional CGM. Learn More The Eversense Sensor is no longer contraindicated for use with some MRI Scans! Click here to learn more. Eversense XL is the world’s first long-term CGM, with exceptional accuracy and a fully insertable sensor that lasts for up to 180 days. It can help you better manage your diabetes 1 by providing real-time insight into your changing glucose levels, which you can discreetly check on your compatible mobile device. People using Eversense say it helps them feel more confident about controlling their diabetes, 2 and we hope it does the same for you. Eversense XL CGM System Up to 180-Days of Sensor Life Other CGM systems require a sensor removal and reinsertion every 2 weeks or more, while the Eversense XL Sensor lasts up to 180 days. Learn More about our Sensor Smart Transmitter Eversense XL offers you the flexibility and discretion to remove the transmitter without wasting a sensor. Discover our Smart Transmitter iOS and Android App With Eversense XL, you can see your readings directly on your compatible mobile device. And with readings every 5 minutes, you can see where you are now and where you’re headed with the trend arrows. 3 Download the Mobile App Eversense XL CGM System Eversense XL is the first and only long-term CMG that has a sensor that is changed only 2-3 times per year by a healthcare provider – no more weekly self-insertions. Eversense provides you with the Freedom you’ve always wanted in a CGM. 288 readings every 24 hours Glucose readings every 5 minutes help you not only where you are, but where you’re going. Trend arrows help you manage your diabetes before going too high or too low. Gentle, non-irritating adhesive Eversense uses a hypoallergenic silicone-based adhesive that’s gentle on the skin. Alerts you can see, feel and hear Eversense XL can send you pop-up messages on your phone, sound an alarm or vibrate on your arm to alert you to highs and lows, based on your customized settings. No Sensor Self-Insertion Eversense XL is inserted by your healthcare provider 2-3 times per year, letting you avoid the burdensome self-insertion process every 7-14 days. Learn More New to CGM Learn about CGM and how Eversense XL can help you manage your diabetes. Learn More Upgrading to Long-Term CGM? Think all CGMs are the same? Learn why Eversense XL is the only long-term CGM. Learn More Payer Learn how Eversense XL can improve real-world outcomes for patients. Learn More Healthcare Providers Find out how long-term CGM can help your patients better manage their diabetes. Learn More 1 Kropff, J., Choudhary, P., Neupane, S., Barnard, K., Bain, S. C., Kapitza, C., ... & DeVries, J. H. (2017). Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial. Diabetes Care, 40(1), 63-68. 2 Christiansen, M. P., Klaff, L. J., Brazg, R., Chang, A. R., Levy, C. J., Lam, D., ... & Kelley, L. (2018). A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technology & Therapeutics. (PRECISE II).7. Glycemic Targets: Standards of Medical Care in Diabetes-2018 Diabetes Care 2018;41(Suppl. 1):S55–S64 3 Data on file. MKT-1101 Rev 2 Important Update: August 10, 2020 Senseonics announces agreement to collaborate with Ascensia Diabetes Care On August 10, 2020 we announced the formation of a collaboration and commercialization agreement between Senseonics, Incorporated and Ascensia Diabetes Care, maker of the CONTOUR ® portfolio of blood glucose monitoring systems. This new agreement begins in 2021 and at the present time does not lead to any changes in how you obtain Eversense XL CGM, how you schedule your insertions and removals, or who you contact if you have any issues. Please continue to use the same contacts you are using now for your needs concerning Eversense XL and for Customer Care. More information will be coming in the future. Sincerely, Francine Kaufman, MD and the Senseonics Leadership Team To read the press release, click here . To learn more about Ascensia Diabetes Care, click here . Disclaimer This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin. The Eversense®XL Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 180 days. It is intended to complement, not replace, fingerstick blood glucose monitoring. The sensor insertion and removal is performed by a health care provider. The Eversense XL CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see global.eversensediabetes.com/safety-info. © 2019 Safety Information EULA Privacy Policy Legal Press Kit Patents...